TAI · 6861.TW
InnoCare Optoelectronics Corporation
NT$213.50-NT$19.00 (-8.17%)
InnoCare Optoelectronics Corporation’s quoted price sits in the lower half of its reported 52-week range, 56.43% below the high.
Loading market information…
TAI · 6598.TW · TWD
Stock price, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Applied BioCode Corporation’s quoted price sits in the upper half of its reported 52-week range, 10.97% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Applied BioCode Corporation’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -NT$0.02. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Applied BioCode Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Applied BioCode Corporation specializes in the complete lifecycle—from design and development to manufacturing and commercialization—of multiplex diagnostic testing solutions tailored for the In-Vitro Diagnostics (IVD) market. Among its key offerings are two sophisticated systems: the BioCode MDx 3000, an automated molecular diagnostics platform that streamlines PCR amplification, hybridization, and detection steps; and the BioCode 2500 analyzer, specifically engineered to read barcoded magnetic beads (BMBs) and display their unique identification along with fluorescence intensity. The company also boasts an extensive portfolio of diagnostic assays, including the BioCode SARS-CoV-2 Assay, a high-throughput, automated nucleic acid multiplex test for detecting SARS-CoV-2 genetic material in nasopharyngeal swabs. Other panels comprise BioCode Respiratory Pathogen Panels, capable of simultaneously identifying and differentiating seventeen distinct respiratory pathogens in nasopharyngeal samples, and BioCode gastrointestinal (GI) pathogen panels, which target prevalent GI pathogens such as viruses, bacteria, and parasites responsible for infectious diarrheal diseases. An expanding pipeline of MDx assays for various molecular tests is also under development. Beyond these, Applied BioCode provides specialized reagents like analyte-specific reagents for fungal pathogens, and multiplex kits for human cytokines and chemokines, vital for biomarker identification. For research flexibility, they offer premixed and customizable multiplex kits for mouse models, alongside similar cytokine/chemokine multiplex kits for rat, monkey, canine, and non-human primate studies. Rounding out its comprehensive services, the company supplies its proprietary BMBs, calibration beads, and coupling kits for a wide array of bioassay applications. They also offer ELISA (Enzyme-Linked Immunosorbent Assay), a method for the precise quantification of drug, protein, or antibody levels in biological samples such as cell lysates or serum, in addition to providing full-spectrum assay development services. Applied BioCode Corporation is headquartered in Santa Fe Springs, California.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 | Mar 13, 2025 | -NT$0.69-114.75% vs estimate | NT$84.98M-37.51% vs estimate |
|---|
| Q3 2024 | Nov 11, 2024 | -NT$0.80-135.29% vs estimate | NT$74.95M-44.89% vs estimate |
|---|
| Q2 2024 | Aug 29, 2024 | -NT$0.61-19.61% vs estimate | NT$101.64M+10.47% vs estimate |
|---|
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$213.50-NT$19.00 (-8.17%)
InnoCare Optoelectronics Corporation’s quoted price sits in the lower half of its reported 52-week range, 56.43% below the high.
NT$5.22-NT$0.26 (-4.74%)
Medtecs International Corporation Limited’s quoted price sits in the lower half of its reported 52-week range, 26.48% below the high.
NT$21.30-NT$0.15 (-0.7%)
GlycoNex Incorporation’s quoted price sits in the lower half of its reported 52-week range, 29.0% below the high.
NT$23.35-NT$0.55 (-2.3%)
Wellell Inc.’s quoted price sits in the lower half of its reported 52-week range, 9.85% below the high.
NT$50.00-NT$0.50 (-0.99%)
MedFirst Healthcare Services, Inc.’s quoted price sits in the lower half of its reported 52-week range, 20.26% below the high.
NT$16.80-NT$0.25 (-1.47%)
OK Biotech Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 8.75% below the high.
NT$9.42-NT$0.25 (-2.59%)
Sunny Pharmtech Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.54% below the high.
NT$53.20-NT$0.20 (-0.37%)
Medical Imaging Corporation’s quoted price sits in the lower half of its reported 52-week range, 36.06% below the high.
